APA

Haberkorn U., Reinhardt M., Strauss L. G., Oberdorfer F., Berger M. R., Altmann A., Wallich R., Dimitrakopoulou A. & van Kaick G. (19921208). Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. : Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Chicago

Haberkorn U, Reinhardt M, Strauss L G, Oberdorfer F, Berger M R, Altmann A, Wallich R, Dimitrakopoulou A and van Kaick G. 19921208. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. : Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Harvard

Haberkorn U., Reinhardt M., Strauss L. G., Oberdorfer F., Berger M. R., Altmann A., Wallich R., Dimitrakopoulou A. and van Kaick G. (19921208). Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. : Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

MLA

Haberkorn U, Reinhardt M, Strauss L G, Oberdorfer F, Berger M R, Altmann A, Wallich R, Dimitrakopoulou A and van Kaick G. Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy. : Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 19921208.